|
1
|
Kang MG, Choi HW, Lee JH, Choi YJ, Choi
HJ, Shin JH, Suh SP, Szardenings M, Kim HR and Shin MG: Coexistence
of JAK2 and CALR mutations and their clinical implications in
patients with essential thrombocythemia. Oncotarget. 7:57036–57049.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barosi G, Birgegard G, Finazzi G,
Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ,
Lengfelder E, McMullin MF, Passamonti F, et al: Response criteria
for essential thrombocythemia and polycythemia vera: Result of a
European LeukemiaNet consensus conference. Blood. 113:4829–4833.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barbui T, Thiele J, Gisslinger H, Finazzi
G, Vannucchi AM and Tefferi A: The 2016 revision of WHO
classification of myeloproliferative neoplasms: Clinical and
molecular advances. Blood Rev. 30:453–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Micol JB and Abdel-Wahab O: The Role of
Additional Sex Combs-Like Proteins in Cancer. Cold Spring Harb
Perspect Med. 6:pii: a026526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katoh M: Functional and cancer genomics of
ASXL family members. Br J Cancer. 109:299–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdel-Wahab O, Adli M, LaFave LM, Gao J,
Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, et al:
ASXL1mutations promot myeloid transformation through loss of
PRC2-mediated gene repression. Cancer Cell. 22:180–193. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang J, Ge M, Lu S, Shi J, Li X, Zhang J,
Wang M, Yu W, Shao Y, Huang Z, et al: Mutations of ASXL1 and TET2
in aplastic anemia. Haematologica. 100:e172–e175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshizato T, Dumitriu B, Hosokawa K,
Makishima H, Yoshida K, Townsley D, Sato-Otsubo A, Sato Y, Liu D,
Suzuki H, et al: Somatic mutations and clonal hematopoiesis in
aplastic anemia. N Engl J Med. 373:35–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gelsi-Boyer V, Trouplin V, Adélaïde J,
Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prebet T, Nezri M,
Sainty D, et al: Mutations of polycomb-associated gene ASXL1 in
myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br
J Haematol. 145:788–800. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gelsi-Boyer V, Brecqueville M, Devillier
R, Murati A, Mozziconacci MJ and Birnbaum D: Mutations in ASXL1 are
associated with poor prognosis across the spectrum of malignant
myeloid diseases. J Hematol Oncol. 5:122012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gill H, Leung AY and Kwong YL: Molecular
and cellular mechanisms of myelodysplastic syndrome: Implications
on targeted therapy. Int J Mol Sci. 17:4402016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vannucchi AM, Lasho TL, Guglielmelli P,
Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N,
Mannarelli C, et al: Mutations and prognosis in primary
myelofibrosis. Leukemia. 27:1861–1869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrer-Marin F, Bellosillo B,
Martínez-Avilés L, Soler G, Carbonell P, Luengo-Gil G, Caparros E,
Torregrosa JM, Besses C and Vicente V: Leukemic transformation
driven by an ASXL1 mutation after a JAK2V617F-positive primary
myelofibrosis: Clonal evolution and hierarchy revealed by
next-generation sequencing. J Hematol Oncol. 6:682013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shih AH, Abdel-Wahab O, Patel JP and
Levine RL: The role of mutations in epigenetic regulators in
myeloid malignancies. Nat Rev Cancer. 12:599–612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Viny AD and Levine RL: Genetics of
myeloproliferative neoplasms. Cancer J. 20:61–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Milosevic JD and Kralovics R: Genetic and
epigenetic alterations of myeloproliferative disorders. Int J
Hematol. 97:183–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al Assaf C, Van Obbergh F, Billiet J,
Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T,
De Paepe P, et al: Analysis of phenotype and outcome in essential
thrombocythemia with CALR or JAK2 mutations. Haematologica.
100:893–897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Imai M, Araki M and Komatsu N: Somatic
mutations of calreticulin in myeloproliferative neoplasms. Int J
Hematol. 105:743–747. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clinton A and McMullin MF: The
Calreticulin gene and myeloproliferative neoplasms. J Clin Pathol.
69:841–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tefferi A: JAK and MPL mutations in
myeloid malignancies. Leuk Lymphoma. 49:388–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji L, Qian M, Wu N and Wu J: Significance
of combined detection of JAK2V617F, MPL and CALR gene mutations in
patients with essential thrombocythemia. Exp Ther Med. 13:947–951.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Zhang B, Chen B, Zhou RF, Zhang
QG, Li J, Yang YG, Zhou M, Shao XY, Xu Y, et al: JAK2, MPL, and
CALR mutations in Chinese Han patients with essential
thrombocythemia. Hematology. 22:145–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao S, Zhang X, Xu Y, Feng Y, Sheng W,
Cen J, Wu D and Han Y: Impact of JAK2V617F mutation burden on
disease phenotype in Chinese patients with JAK2V617F-positive
polycythemia vera (PV) and essential thrombocythemia (ET). Int J
Med Sci. 13:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barbui T, Finazzi G, Carobbio A, Thiele J,
Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi
I, et al: Development and validation of an International Prognostic
Score of thrombosis in World Health Organization-essential
thrombocythemia (IPSET-thrombosis). Blood. 120:5128–5133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paschka P, Schlenk RF, Gaidzik VI, Herzig
JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne
CH, et al: ASXL1 mutations in younger adult patients with acute
myeloid leukemia: A study by the German-Austrian Acute Myeloid
Leukemia Study Group. Haematologica. 100:324–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Passamonti F, Maffioli M, Merli M,
Ferrario A and Caramazza D: Clinical predictors of outcome in MPN.
Hematol Oncol Clin North Am. 26:1101–1116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barbui T, Thiele J, Passamonti F, Rumi E,
Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi
I, et al: Survival and disease progression in essential
thrombo-cythemia are significantly influenced by accurate
morphologic diagnosis: An international study. J Clin Oncol.
29:3179–3184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shrestha R, Giri S, Pathak R and Bhatt VR:
Risk of second primary malignancies in a population-based study of
adult patients with essential thrombocythemia. World J Clin Oncol.
7:324–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suleiman Y, Dalia S, Liu JJ, Bowers JW,
Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman
KS and Zhang L: Clinical prognostic factors and outcomes of
essential thrombocythemia when transformed to myelodysplastic
syndromes and acute myeloid leukemia. Leuk Res. 42:52–58. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen H, Chao H, Ding Z, Feng Y, Cen J, Pan
J, He J, Zhou M, Chen Z and Chen S: CALR and ASXL1 mutation
analysis in 190 patients with essential thrombocythemia. Leuk
Lymphoma. 56:820–822. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abdel-Wahab O, Kilpivaara O, Patel J,
Busque L and Levine RL: The most commonly reported variant in ASXL1
(c.1934dupG;p. Gly646TrpfsX12) is not a somatic alteration.
Leukemia. 24:1656–1657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stein BL, Williams DM, O'Keefe C, Rogers
O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA
and Moliterno AR: Disruption of the ASXL1 gene is frequent in
primary, post-essential thrombocytosis and post-polycythemia vera
myelofibrosis, but not essential thrombocytosis or polycythemia
vera: Analysis of molecular genetics and clinical phenotypes.
Haematologica. 96:1462–1469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rumi E and Cazzola M: How I treat
essential thrombocythemia. Blood. 128:2403–2414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vainchenker W, Constantinescu SN and Plo
I: Recent advances in understanding myelofibrosis and essential
thrombocythemia. F1000Res 5: pii: F1000 Faculty Rev-700. 2016.
|
|
35
|
Aruch D and Mascarenhas J: Contemporary
approach to essential thrombocythemia and polycythemia vera. Curr
Opin Hematol. 23:150–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barbui T, Thiele J, Vannucchi AM and
Tefferi A: Myeloproliferative neoplasms: Morphology and clinical
practice. Am J Hematol. 91:430–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
